Achillion Pharmaceuticals (ACHN) Raised At Deutsche Bank

Achillion Pharmaceuticals, Inc. (ACHN), one of last weeks top percentage-gainers, was upgraded this morning by analysts at Deutsche Bank (DB) to a ‘Buy’ rating from a ‘Hold’ rating. The research firm also raised its price target on the stock to $17 from $6 a share, which represents a potential upside of 83.78% from its Friday […] View the full post at: Achillion Pharmaceuticals (ACHN) Raised At Deutsche Bank Related posts: Moody’s Downgrades Deutsche Bank to Aa3 Moody’s Upgrades (JAS, F, COT) Strategic Capital Bank, Champaign, Illinois: 09′s Bank Failure #35